Prurigo

• EMA approval · 2026-08-18
  EMA Authorised: Dupixent (dupilumab) — Sanofi Winthrop Industrie

  The EMA has authorised Dupixent (dupilumab) for multiple indications including atopic dermatitis, prurigo, esophageal diseases, asthma, and …

• EMA approval · 2026-03-02
  EMA Authorised: Nemluvio (nemolizumab) — Galderma International

  The European Medicines Agency has authorised nemolizumab (Nemluvio) for use in atopic dermatitis and prurigo, marking a new monoclonal antib…

• CLINICAL_TRIALS trial_result · 2021-07-16
  Clinical Trial Update: Topical Aprepitant in Prurigo Patients [Phase 2]

  Phase 2 trial results were posted for a topical formulation of aprepitant in patients with prurigo. The study was sponsored by LEO Pharma an…

• CLINICAL_TRIALS research · 2013-06-05
  Clinical Trial Update: Dapsone Prurigo Study [NA]

  A clinical trial update for a dapsone study in prurigo and lichen simplex chronicus with an unknown status.